Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.61 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 2/20 | 0.46 |
| ▸ | FNTB | P49356 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | CDC25A | P30304 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4294255 | 0.89 | NR4A1 (0.69) | NR4A1SRD5A2TSHRALOX15KDM4E | |
| SCHEMBL30819719 | 0.85 | CES2 (0.55) | NR4A1KDM4EMAPK1TDP1CDC25A | |
| SCHEMBL1821471 | 0.85 | NR4A1 (0.65) | NR4A1SRD5A2TSHRALOX15KDM4E | |
| SCHEMBL1822747 | 0.83 | NR4A1 (0.62) | NR4A1SRD5A2TSHRALOX15KDM4E | |
| SCHEMBL1819626 | 0.83 | NR4A1 (0.62) | NR4A1SRD5A2TSHRALOX15KDM4E | |
| SCHEMBL25181022 | 0.82 | NR4A1 (0.61) | NR4A1SRD5A2TSHRALOX15KDM4E | |
| SCHEMBL11731147 | 0.81 | NR4A1 (0.70) | NR4A1SRD5A2TSHRALOX15KDM4E | |
| SCHEMBL5058715 | 0.81 | NR4A1 (0.69) | NR4A1SRD5A2TSHRALOX15KDM4E | |
| SCHEMBL18249820 | 0.80 | POLB (0.49) | NR4A1KDM4EMAPTHSD17B10ALDH1A1 | |
| SCHEMBL28775847 | 0.80 | KDM4E (0.73) | NR4A1SRD5A2TSHRALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298005-B1 | ANTI-CANCER COMPOUNDS | UNIV CALIFORNIA (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11708352-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220267307-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-08-25 | — | — | US | disclosed |
| US-11149025-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210009562-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-01-14 | — | — | US | disclosed |
| US-10562886-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180354932-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-12-13 | — | — | US | disclosed |
| EP-3298005-A2 | ANTI-CANCER COMPOUNDS | The Regents of The University of California (US) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016187620-A2 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562886-B2 | Anti-cancer compounds | TP53, VHL, BAD | NR4A1 4143/4885SRD5A2 2297/4885TSHR 4809/4885 |
| US-20180354932-A1 | ANTI-CANCER COMPOUNDS | TP53, VHL, BAD | NR4A1 4143/4885SRD5A2 2297/4885TSHR 4809/4885 |
| US-20210009562-A1 | ANTI-CANCER COMPOUNDS | TP53, VHL, BAD | NR4A1 4143/4885SRD5A2 2297/4885TSHR 4809/4885 |
| US-11708352-B2 | Anti-cancer compounds | TP53, VHL, BAD | NR4A1 4143/4885SRD5A2 2297/4885TSHR 4809/4885 |
| US-20220267307-A1 | ANTI-CANCER COMPOUNDS | TP53, VHL, BAD | NR4A1 4143/4885SRD5A2 2297/4885TSHR 4809/4885 |
| US-11149025-B2 | Anti-cancer compounds | TP53, VHL, BAD | NR4A1 4143/4885SRD5A2 2297/4885TSHR 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.